Background
==========

Almost as soon as the widespread therapeutic use of antibiotics occurred, bacteria displaying diverse and complex mechanisms of resistance became problematic \[[@B1],[@B2]\]. As the human gut is one of the most densely populated microbial environments, it has been postulated that it can act as a considerable reservoir for antibiotic resistance genes \[[@B3]\]. Thus, gut microbes may disseminate antibiotic resistance genes to other commensals or to bacteria transiently colonising the gut \[[@B4]\]. Given that antibiotics are known to exert significant and sustained negative effects on the gut microbiota \[[@B5],[@B6]\], possessing resistance genes can provide a significant selective advantage to a subpopulation of microorganisms in individuals undergoing antibiotic treatment \[[@B7]\]. The aminoglycosides and β-lactams are two large families of antibiotics which are frequently employed in clinical settings. The aminoglycosides, which were first characterised in 1944, \[[@B8]\] function by binding to the 30S subunit of the prokaryotic ribosome resulting in disruption to protein synthesis. Resistance to aminoglycosides can be through reduced aminoglycoside uptake or enzymatic modification of the aminoglycoside through acetylation (AAC), adenylation (ANT) or phosphorylation (APH). β-lactam antibiotics include the penicillins and cephalosporins and inhibit bacteria through disruption of cell wall biosynthesis \[[@B9],[@B10]\]. Resistance to β-lactams can be due to alterations to penicillin binding proteins or to the porins in the outer membrane (in Gram negative targets) or alternatively through the production of β-lactamases, which hydrolyse the eponymous β-lactam ring rendering the antibiotic inactive \[[@B11],[@B12]\].

The question of the evolutionary origin of antibiotic resistance genes has been the subject of much attention \[[@B9],[@B13],[@B14]\]. For quite some time it was thought that resistance evolved following exposure of bacteria to new antibiotics \[[@B15]\]. However, it is now apparent that repositories of antibiotic resistance genes exist such that, following the development and application of new antibiotics, bacteria possessing or acquiring such genes will gain a selective advantage and thus resistance will increase over time \[[@B16],[@B17]\]. Previous studies have employed PCR to detect resistance genes in specific pathogens \[[@B18],[@B19]\], though studies employing PCR to detect resistance genes in complex microbial environments have been limited. In one instance, a PCR-based approach was used to investigate the prevalence of gentamycin resistance genes in resistant isolates from sewage, faeces (from cattle and chickens), municipal and hospital sewage water and coastal water \[[@B20]\]. The utilisation of a PCR approach in that instance resulted in the identification of diverse genes encoding gentamycin modifying enzymes from across a broad host range, thus demonstrating the suitability of a PCR-based approach to investigate resistance genes present in complex environments. However, the study did not investigate antibiotic resistance genes in human gut microbiota and, to our knowledge, to date no such PCR-based studies exist. Given these findings and other indications that there exist large natural pools of antibiotic resistance genes within complex microbial populations, it is likely that the human gut also contains many such genes. However, until now, PCR-based strategies to detect antibiotic resistance genes in the gut microbiota have involved an initial culture-based screen for resistant isolates, followed by subsequent PCR-based approaches to identify the associated resistance genes. This does not take into consideration the fact that the vast majority of gut microbes are not easily cultured \[[@B21]\], and thus antibiotic resistance genes from such microorganisms would typically be overlooked.

Here we utilise degenerate PCR primers to investigate the presence of β-lactam resistance genes and each of the three categories of aminoglycoside modifying enzymes within human metagenomic DNA and in doing so demonstrate that the human gut microbiota is a reservoir for antibiotic resistance genes. Additionally, we establish that a PCR-based approach allows the rapid detection of such genes in the complex gut microbiota environment, without the need for an initial isolation of strains.

Methods
=======

Recruitment of volunteers
-------------------------

Forty adults were recruited and each provided written, informed consent for participation in this study. Approval for this trial was received from the Clinical Research Ethics Committee of the Cork Teaching Hospitals, Cork, Ireland. Volunteers were aged 28.8 ± 3.8 years, were free from gastrointestinal disorders and had not been treated with antibiotics in the 6 months prior to sample collection. Fresh faecal samples were collected and stored at −80°C until processed.

DNA extraction
--------------

Stool samples were weighed, homogenised and due to the total volume provided by each individual, samples had to be pooled to achieve the required volume for our metagenomic DNA extraction protocol. To facilitate this, an equal volume (250 mg) from each individual was taken and pooled to form one sample, from which metagenomic DNA was extracted. The DNA extraction procedure used was optimised for total bacterial genomic DNA extraction from stool samples. The stool sample was homogenized in PBS and centrifuged at 1000 g × 5 mins and the supernatant was removed and retained. This was repeated 3 times. The supernatant then underwent Nycodenz (Axis Shield, UK) density gradient centrifugation separation, to separate out the bacterial cells from faecal matter. Following enzymatic lysis of bacterial cells using lysozyme and mutanolysin (Sigma Aldrich, Dublin, Ireland) protein precipitation using Proteinase K and ammonium acetate (Sigma Aldrich) was completed. Bacterial DNA was then precipitated and washed using standard chloroform and ethanol procedures. DNA was eluted in TE buffer.

PCR-based detection of β-lactam resistance gene homologues
----------------------------------------------------------

PCR-based detection of β-lactam resistance genes was completed using primers (MWG Eurofins, Germany) for the genes *bla*~TEM~\[[@B22],[@B23]\], *bla*~SHV~\[[@B24]\] (both of which are classified as Bush group 2b β-lactamases), *bla*~CTX-M~\[[@B25]\] (an extended spectrum β-lactamase (ESBL) which confers resistance to cefotaxime), *bla*~OXA~\[[@B24]\] (ESBL, Bush group 2d ESBL) and *bla*~ROB~\[[@B23]\] (confers high level ampicillin resistance) (Table [1](#T1){ref-type="table"}). PCRs were completed using bacterial metagenomic DNA and all PCRs were performed in triplicate. PCRs were completed on a G-storm PCR machine and for the primer sets *bla*~TEM~ primer set 1 (RH605/606), *bla*~TEM~ primer set 2 and *bla*~CTX-M~, PCRs were completed as previously outlined. For the primers *bla*~OXA~ and *bla*~ROB~ the PCR conditions were as follows: heated lid 110°C, 94°C × 5 mins followed by 30 cycles of 94°C × 30s, 64°C × 30s (*bla*~oxa~) or 62°C (*bla*~ROB~) and 72°C × 30s followed by 72°C × 10 mins and held at 4°C. For *bla*~SHV~ PCRs were performed as follows: heated lid 110°C, 94°C × 5 mins followed by 35 cycles of 94°C × 30s, 58°C × 30s and 72°C × 30s followed by a final extension step of 72°C × 10 mins and held at 4°C. All PCRs contained 25 μl Biomix Red (Bioline, UK), 1 μl forward primer (10pmol concentration), 1 μl reverse primer (10pmol concentration), metagenomic DNA (64 ng) and PCR grade water (Bioline, UK), to a final volume of 50 μl. Negative controls were completed for all primer sets. Gel electrophoresis was performed on all samples using 1.5% agarose gel in 1× TAE buffer.

###### 

Primers used for the detection of β-lactamase and aminoglycoside resistant genes

  **Location**                       **Primer**                  **Sequence 5′-3′**                   **Amplicon Size (bp)**   **Annealing Temp°C**                      **Source**
  --------------------------------- ------------ --------------------------------------------------- ------------------------ ---------------------- --------------------------------------------------
  **β-lactamase genes**                                                                                                                                                       
  *Bla*~TEM~                           RH605                    TTTCGTGTCGCCCTTATTCC                           692                      60                   Bailey *et al.* (2011) \[[@B22]\]
                                       RH606                    CCGGCTCCAGATTTATCAGC                                                                                          
                                      Bla_TEMF                  TGGGTGCACGAGTGGGTTAC                           526                      57                   Tenover *et al.* (1994) \[[@B23]\]
                                      Bla_TEMR                  TTATCCGCCTCCATCCAGTC                                                                                          
  *Bla*~ROB~                          Bla_ROBF                  ATCAGCCACACAAGCCACCT                           692                      62                   Tenover *et al.* (1994) \[[@B23]\]
                                      Bla_ROBR                  GTTTGCGATTTGGTATGCGA                                                                                          
  *Bla*~SHV~                          Bla_SHVF                   CACTCAAGGATGTATTGTG                           885                      58                   Briñas *et al.* (2002) \[[@B24]\]
                                      Bla_SHVR                   TTAGCGTTGCCAGTGCTCG                                                                                          
  *Bla*~OXA~                          Bla_OXAF                  TTCAAGCCAAAGGCACGATAG                          702                      64                   Briñas *et al.* (2002) \[[@B24]\]
                                      Bla_OXAR                  TCCGAGTTGACTGCCGGGTTG                                                                                         
  *Bla*~CTX-M~                       Bla_CTX-MF   CGTTGTAAAACGACGGCCAGTGAATGTGCAGYACCAGTAARGTKATGGC            600                      55                  Monstein *et al.* (2009) \[[@B25]\]
                                                                                                                                                                              
                                     Bla_CTX-MR             TGGGTRAARTARGTSACCAGAAYCAGCGG                                                                                     
  **AG resistant genes**                                                                                                                                                      
  *aac* (3)-I                         Faac3-1                  TTCATCGCGCTTGCTGCYTTYGA                         239                      58                    Heuer *et al.* (2002) \[[@B20]\]
                                      Raac3-1                  GCCACTGCGGGATCGTCRCCRTA                                                                                        
  *aac* (3)-II/VI                     Faac3-2                  GCGCACCCCGATGCMTCSATGG                          189                      58                                    
                                      Raac3-2                  GGCAACGGCCTCGGCGTARTGSA                                                                                        
                                      Facc3-6                  GCCCATCCCGACGCATCSATGG                                                                                         
                                      Raac3-6                  CGCCACCGCTTCGGCATARTGSA                                                                                        
  *aac* (6′)-II/Ib                     Faac6                   CACAGTCGTACGTTGCKCTBGG                          235                      58                                    
                                       Raac6                   CCTGCCTTCTCGTAGCAKCGDAT                                                                                        
  *ant* (2′)-I                          Fant                   TGGGCGATCGATGCACGGCTRG                          428                      58                                    
                                        Rant                   AAAGCGGCACGCAAGACCTCMAC                                                                                        
  *aph* (2″)-I                         Faphc                   CCCAAGAGTCAACAAGGTGCAGA                         527                      55                                    
                                       Faphd                   GGCAATGACTGTATTGCATATGA                         572                      55                                    
                                        Raph                   GAATCTCCAAAATCRATWATKCC                                                                                        
  *aac* (6′)-*Ie*-*aph* (2″)-*Ia*     aac-aphF                GAGCAATAAGGGCATACCAAAAATC                        505                      47            *De Fatίma Silva Lopes et al.* (2003) \[[@B26]\]
                                      aac-aphR                CCGTGCATTTGTCTTAAAAAACTGG                                                                                       
                                     aac6-aph2F                CCAAGAGCAATAAGGGCATACC                          222                      55                   Schmitz *et al.* (1999) \[[@B27]\]
                                     aac6-aph2R                CACACTATCATAACCATCACCG                                                                                         

*AG*: aminoglycoside. Type of gene i.e. beta-lactamase or AG given in bold.

PCR-based detection of aminoglycoside resistance gene homologues
----------------------------------------------------------------

For the detection of aminoglycoside resistant genes, degenerate primer sets were used which had previously been designed and shown to amplify all known genes encoding gentamycin-modifying enzymes and similar, but as yet undiscovered, sequences \[[@B20]\]. PCRs were completed using primer sets (MWG Eurofins, Germany) for genes belonging to each group of aminoglycoside modifying enzymes namely, acetylation, adenylation and phosphorylation enzymes. DNA from positive controls (kindly gifted to us from the Smalla laboratory, JKI, Braunschweig) namely *Escherichia coli* S17-1 pAB2002 (*aac* (3)-Ia), *Pseudomonas aeruginosa* 88.341 F (*aac* (3)-Ib), *Enterobacter aerogenes* 17798 VDK (*aac* (3)-IIa), *E. coli* DH5α pSCH4203 (*aac* (3)-IIb), *E. coli* DH5α pSCH4101 (*aac* (3)-VIa), *P. aeruginosa* PST-1 (*aac* (3)-IIIa), *Acinetobacter baumannii* LBL.3 (*aac* (6′)-Ib), *P. aeruginosa* F-03 (*aac* (6′)-IIa), *E. coli* DH5α pSCH5102 (*aac* (6′)-IIb), *E. coli* CV600 pIE723 (*ant* (2″)-I), *E. coli* DH5α pAM6306 (*aph* (2″)-Ic) and *E. coli* NC95 (*aph* (2″)-Id) were used as positive controls for the PCR reactions. This ensured the specificity of the respective primer pairs. PCRs for the detection of acetylation genes *aac* (3)-I, *aac* (3)-II, *aac* (3)-III, *aac* (3)-VI and *aac* (6), adenylation genes *ant* (2″)-Ia and phosphorylation genes *aph* (2″)-Ic and *aph* (2″)-Id were completed as previously outlined \[[@B20]\] (Table [1](#T1){ref-type="table"}). Additionally, PCRs using primers for the bifunctional gene *aac* (6″)-*Ie-aph* (2″) \[[@B26],[@B27]\] (which encodes enzymes responsible for high level gentamycin resistance, as well as concomitant resistance to tobramycin and kanamycin) \[[@B27]-[@B31]\] were completed as follows: heated lid 110°C, 94°C × 5 mins followed by 30 cycles of 94°C × 30s, 47°C × 30s, 72°C × 30s, with a final extension step of 72°C × 10 mins and held at 4°C. All PCRs contained 25 μl Biomix Red (Bioline, UK), 1 μl forward primer (10pmol concentration), 1 μl reverse primer (10pmol concentration), metagenomic DNA (64 ng) and PCR grade water (Bioline, UK), to a final volume of 50 μl. Negative controls were run for all primer sets. All PCRs were performed in triplicate and analysed using gel electrophoresis, as described above.

Cloning of PCR amplicons
------------------------

Triplicate samples from successful PCR reactions were pooled and cleaned using AMPure magnetic bead-based PCR clean up kit (Beckman Coulter, UK). TOPO cloning reactions were performed on purified PCR products using the TOPO TA cloning kit (Invitrogen, Dublin, Ireland) to facilitate the sequencing of individual gene fragments. TOPO cloning reactions were then cloned into TOP10 *E. coli* (Invitrogen) as per the manufacturer's instructions and plated onto LB (Difco) containing the appropriate antibiotic (either ampicillin 50 μg/ml or kanamycin 50 μg/ml; Sigma Aldrich, Dublin, Ireland) to select for the presence of the cloning vector. Transformants were selected from each TOPO cloning reaction and grown overnight in LB broth containing the suitable selective antibiotic (either ampicillin 50 μg/ml or kanamycin 50 μg/ml). Plasmids were extracted from overnight samples using QIAprep Spin Mini Prep kit (Qiagen, Sussex, UK) according to the manufacturer's instructions and sent for Sanger sequencing (Source BioSciences, Dublin, Ireland).

Bioinformatic analysis
----------------------

Following Sanger sequencing, sequence reads were analysed using the NCBI protein database (BlastX; (<http://blast.ncbi.nlm.nih.gov/>)). In the event where multiple hits occurred, the BLAST hit which displayed greatest homology is reported.

Results and discussion
======================

A PCR-based approach highlights the presence of β-lactamase gene homologues in the gut microbiota
-------------------------------------------------------------------------------------------------

The results of the β-lactamase-specific PCRs demonstrated the presence and diversity of class 2 β-lactamase genes in the gut microbiota of healthy adults (Table [2](#T2){ref-type="table"}\[[@B32]\]). Of the β-lactam primers used, the primers designed to amplify *bla*~TEM~ genes yielded the greatest number of unique sequence hits (42% of selected TOPO sub-clones gave a unique hit). The majority of these genes exhibited a high percentage identity with genes from various members of the *Proteobacteria* including *E. coli*, *Klebsiella*, *Salmonella*, *Serratia, Vibrio parahaemolyticus* and *Escherichia vulneris*. The resistance of strains of *Salmonella* and *Serratia* to β-lactams via *bla*~TEM~ genes has been noted \[[@B33]-[@B35]\] and such strains have been associated with nosocomial infections \[[@B36]\]. In contrast, there have been relatively few studies of *bla*~TEM~ genes in *Vibrio parahaemolyticus* and *Escherichia vulneris*\[[@B37],[@B38]\]. The identification of genes homologous to those from *Enterobacteriaceae* is not surprising given the prevalence of resistance genes among members of this family \[[@B12]\]. It was notable that the *bla*~TEM~ primers also amplified genes that resembled *bla*~TEM~ genes from some more unusual sources, including two genes from uncultured bacteria and from a Sar 86 cluster (a divergent lineage of γ-*Proteobacteria*) bacteria. This approach can thus provide an insight into possible novel/unusual sources of resistance genes, including those that culture-based approaches would fail to detect. Such results also highlight that had initial screening for resistant isolates been completed prior to PCR amplification of the resistance genes, such unusual sources of resistance genes may have been overlooked. Additionally, genes encoding ESBLs, including *bla*~TEM-116~, *bla*~TEM-195~ and *bla*~TEM-96~ amongst others, were also identified, with their closest homologues being members of the *Proteobacteria* (Table [2](#T2){ref-type="table"}).

###### 

Homologues of β-lactamase genes detected in the human gut microbiota via PCR techniques

  **Accession \#**              **Gene description**                **Closest homologue**          **E value**   **% identity**
  ---------------------- ---------------------------------- ------------------------------------- ------------- ----------------
  ***Bla***~**TEM**~                                                                                                    
  ADE18890.1                     β-lactamase TEM-1             *S. enterica* subsp. *enterica*      5e^-154^           99
  AAS46844.1                     β-lactamase TEM-1                     *S. marcescens*              2e^-156^          100
  AEN02824.1                     β-lactamase TEM-1                     *K. pneumoniae*              3e^-111^           99
  AEN02817.1                     β-lactamase TEM-1                     *K. pneumoniae*              1e^-113^           99
  ACV88636.1                     β-lactamase TEM-1                        *E. coli*                 2e^-151^           99
  AEL87577.1                   ES β-lactamase TEM-116             *Vibrio parahaemolyticus*         5e^-154^           99
  AEQ55231.1                     β-lactamase TEM-1                        *E. coli*                  1e^-35^           45
  ABQ14376.1                        β-lactamase                  *Uncultured soil bacterium*         6e^-05^           83
  ADN79104.1                      β-lactamase TEM                  *Escherichia vulneris*            1e^-15^           86
  WP_010157942.1                  β-lactamase TEM                *Sar 86 cluster bacterium*         9e^-122^           83
  ACI29961.1                     β-lactamase TEM-1                        *E. coli*                 2e^-153^           99
  AEQ39590.1                    β-lactamase TEM-195                       *E. coli*                  5e^-93^           96
  AAM22276.1                     β-lactamase TEM-96                       *E. coli*                 7e^-139^           94
  WP_019405145.1                  β-lactamase TEM                      *K. pneumoniae*              4e^-155^           99
  AEW28787.1                     β-lactamase TEM-1                 *Uncultured bacterium*           1e^-133^          100
  ABY81267.1                        β-lactamase                           *E. coli*                 4e^-156^          100
  AAF74292.1                       ES β-lactamase                         *E. coli*                 5e^-155^           99
  AFU53026.1                     KPC-2 β lactamase                     *S. marcescens*              2e^-112^           98
  ADE18896.1                     β-lactamase TEM-1                  *Salmonella enterica*           2e^-113^           99
  AEN02826.1                     β-lactamase TEM-1                     *K. pneumoniae*              4e^-113^           99
  ***Bla***~**ROB**~                                                                                                    
  YP_252228.1               Hypothetical protein SH0313               *S. haemolyticus*              2e^-33^           44
  ***Bla***~**SHV**~                                                                                                    
  WP_009348253.1          Hypothetical protein HMPREF 9332          *Alloprevotella rava*            3e^-07^           56
  WP_017896153.1                    β-lactamase              *K. pneumoniae* subsp. *pneumoniae*       0.0             99
  WP_008157744.1          Hypothetical protein HMPREF 1077       *Parabacteroides johnsonii*           1.5             29
  CAJ47138.2                        β-lactamase                        *K. pneumoniae*                 0.0             99
  ADU15837.1                         BlaSHV132                         *K. pneumoniae*                 0.0             99
  AEK80394.1                     β-lactamase SHV140                    *K. pneumoniae*                 0.0             99
  ABS72351.1                     β-lactamase SHV103                    *K. pneumoniae*                 0.0             99
  AAP03063.1                     β-lactamase SHV48                     *K. pneumoniae*                 0.0             99
  AEG79634.1                   ES β-lactamase SHV120                      *E. coli*                                    99
  ***Bla***~**CTX-M**~                                                                                                  
  ABG46354.1                       ES β-lactamase                         *E. coli*                 3e^-139^           99
  AEZ49563.1                    β-lactamase CTX-M-1                       *E. coli*                 2e^-138^           99
  AEZ49551.1                    β-lactamase CTX-M-1                    *K. pneumoniae*              1e^-139^          100
  ABG46356.1                       ES β-lactamase                      *K. pneumoniae*              9e^-139^           97
  ABW06480.1                  ES β lactamase CTX-M-15                  *K. pneumoniae*               6e^-51^           94
  AAB22638.1              β-lactamase penicillin hydrolase                *E. coli*                 9e^-140^          100
  BAD16611.1                    β-lactamase CTX-M-36                      *E. coli*                 8e^-139^           99
  YP_003717483.1                    β-lactamase                           *E. coli*                 2e^-139^          100
  ABN09669.1                    β-lactamase CTX-M-61                    *S. enterica*               2e^-138^          100

*ESBL*: extended spectrum β-lactamase. Gene names are in bold.

Using the *bla*~SHV~ primers, multiple genes sharing homology with genes from members of the *Enterobacteriaceae*, and *Klebsiella* and *E. coli* in particular were detected. In addition, amplicons with low percentage identity to genes from *Alloprevotella rava* and *Parabacteroides johnsonii*, respectively, were also identified. This is again consistent with existing research which states that *Enterobacteriaceae* are the primary source of *bla*~SHV~ genes \[[@B39]-[@B43]\]. Furthermore, the amplicons sequenced resembled various different types of ESBL-encoding SHV genes, including *bla*~SHV-132~, *bla*~SHV-140~ and *bla*~SHV-48~, thus again highlighting the genuine degeneracy of the primers used.

Additional PCRs were completed to identify other ESBLs, specifically CTX-M- and OXA-type β-lactamases (Table [2](#T2){ref-type="table"}). A number of different CTX-M β-lactamases were detected, including CTX-M-1, CTX-M-15 and CTX-M-36. The fact that many of the β-lactamase genes detected using our approach share homology with resistance genes found in members of the phylum *Proteobacteria* is not surprising as, despite being typically less common than the *Bacteroidetes* or *Firmicutes* in the gut microbiota of healthy adults \[[@B21]\], members of this genus have been identified as sources of antibiotic resistance genes and have been frequently associated with nosocomial infections and outbreaks \[[@B36],[@B39],[@B44],[@B45]\]. In the 1990s, TEM- and SHV-type ESBLs were the β-lactamases most frequently observed among *Enterobacteriaceae*\[[@B18]\]. However, more recently, CTX-M-type ESBLs have spread rapidly and are now the most prevalent ESBL in *Enterobacteriaceae* in several parts of the world \[[@B46]\]. In a recent report on antibiotic resistance threats in the USA, the Centre for Disease Control stated that ESBL-producing *Enterobacteriaceae* were a serious public health threat \[[@B47]\]. The report estimates that 26,000 infections and 1,700 deaths that occur each year in the United States are attributable to ESBLs and that upwards of 140,000 health-care related *Enterobacteriaceae* infections occur annually. Therefore the detection of homologues of ESBL-encoding genes in the gut microbiota of healthy individuals is significant and provides evidence of the ubiquitous nature of these resistance genes, even in the absence of recent antibiotic exposure. With respect to the CTX-M-type ESBLs, it is particularly notable that homologues of the *bla*~CTX-M-15~ gene were detected, as these have received significant attention due to their recent rapid spread and their association with multi-drug resistant *E. coli* responsible for outbreaks of antibiotic resistant infections \[[@B48],[@B49]\]. In such cases, these genes have been found on multi-drug resistance-encoding regions of plasmids, thus facilitating the rapid transfer of these genes. The presence of such genes within the gut microbiota raises concerns that horizontal gene transfer may occur between commensals or to bacteria passing through the gut. If the resistance genes detected in our study are, or were to become, mobile, it would enable the gut to act not only as a source of resistance genes, but also as a site of resistance gene transfer. Although outside the scope of this study, studies investigating whether these genes are located on or near mobile genetic elements would be pertinent to ascertain the risk of the gut acting as a site for horizontal gene transfer.

When the *bla*~ROB~ primer set was employed to detect the presence of homologues of these ampicillin resistance-encoding genes, all amplicons sequenced were identical and shared 44% identity to *Staphylococcus haemolyticus bla*~ROB~ gene. Finally, this study did not detect *bla*~OXA~ gene homologues in our metagenomic sample. These findings are unexpected and may have occurred as a result of the particular affinity of the primer sets used.

A PCR-based approach highlights the presence of aminoglycoside resistance encoding gene homologues in the gut microbiota
------------------------------------------------------------------------------------------------------------------------

Degenerate primers were selected that amplify genes encoding aminoglycoside modifying enzymes from each of the enzyme modification groups, namely acetylation, adenylation and phosphorylation \[[@B32]\]. When primers were applied to detect acetylation-associated genes, it was established that the primers designed to target *aac* (3)-I, *aac* (3)-II, and *aac* (3)-III homologues did not generate amplicons. In each of these PCR reactions the positive controls successfully amplified, thus we are satisfied that the lack of amplification products for our metagenomic sample is a true result. However, a number of distinct *aac* (6) and *aac* (3)-VI homologues were detected and were found to resemble genes from a variety of genera, including *Acinetobacter*, *Pseudomonas* and *Enterobacter* (Table [3](#T3){ref-type="table"}). The presence of aminoglycoside acetylation genes within these genera has been noted previously \[[@B50]-[@B53]\]. The detection of resistance genes resembling those seen in *A. baumannii* is a concern, as many strains of this species have been shown to exhibit multi-drug resistance \[[@B54],[@B55]\]. In addition, homologues of genes from *Collinsella* and *Salmonella* were also detected. Primers designed to amplify bifunctional *aac* (6′)-*Ie*-*aph* (2′) genes were also employed. Our investigations revealed the presence of homologues of such genes, resembling those from *S. aureus*, *E. faecium* and *S. epidermidis*, all of which are known sources of these genes \[[@B27],[@B56],[@B57]\].

###### 

Homologues of aminoglycoside resistance genes detected in the human gut microbiota via PCR techniques

  **Accession \#**                                   **Gene description**                             **Closest homologue**        **E value**   **% identity**
  ---------------------------- ----------------------------------------------------------------- -------------------------------- ------------- ----------------
  ***aac*(6)**                                                                                                                                          
  AAA25680.1                                       AG 6′-N-acetyltransferase                        *Pseudomonas fluorescens*       4 e^-48^           98
  WP_006234103.1                               Hypothetical protein Colaer00186                     *Collinsella aerofaciens*          0.0             95
  AAS45464.1                                        6′-N-acetyltransferase                                *A. baumannii*             3e^-33^           75
  ***aac*(6′)-*Ie-aph*(2″)**                                                                                                                            
  WP_002304968.1                                      Phosphotransferase                                   *E. faecium*             9e^-108^          100
  WP_001028140.1                                    Acetyltransferase GNAT                                 *S. aureus*              1e^-107^           99
  WP_001028143.1                                    Acetyltransferase GNAT                                 *S. aureus*              1e^-107^           99
  WP_010729367.1                             Bifunctional AAC/APH partial sequence                         *E. faecium*             5e-^106^           99
  AAX82584.1                                   Bifunctional AG modifying enzyme                      *Enterococcus faecalis*        2e^-112^          100
  WP_002417297.1                                    6′ AG acetyltransferase                               *E. faecalis*             3e^-111^           97
  AFR11868.1                    Bifunctional AG 6′-N acetytransferase/2′-AG phosphotransferases          *S. epidermidis*            1e^-43^           99
  AFM29914.1                                     Gentamycin resistance protein                          *Enterococcus* sp.           7e^-45^           97
  ***aph*(2″) Id**                                                                                                                                      
  3SG8_A                              Chain A crystal structure AG 2′ phosphotransferases               *E. casseliflavus*          1e^-110^           98
  3N4T_A                                                 Aph2″ chain a                                  *E. casseliflavus*          2e^-110^           99
  AAT77696.1                                          AG modifying enzyme                                  *E. faecium*              1e^-68^           94
  ***Aph*(2″)-Ic**                                                                                                                                      
  3TDVA                                              AG phosphotransferase                          *Enterococcus gallinarum*        2e^-83^           97
  ***ant*(2″) Ia**                                                                                                                                      
  YP_005176240.1                                  AG 2′--O-adenyltransferase                          *Pasturella mutocida*          2e^-97^          100
  WP_000314377.1                                 2′ AG nucleotidlytransferase                             *A. baumannii*             3e^-94^           99
  WP_000946493.1                                             2′ AG                                        *A. baumannii*             1e^-94^           99
  ACJ47203.1                                         AG adenyltransferase                                   *E. coli*                6e^-94^           99
  ACA48663.14                                        AG adenyltransferase                             *Morganella morganii*          2e^-96^           99
  ***aac*(3)-VI**                                                                                                                                       
  AAA16194.1                                               aac 3--6                                   *Enterobacter cloacae*         2e^-05^           77
  WP_001642188.1                                     AG acetyltransferase                         *S. enterica* subsp *enterica*     2e^-20^           98

*AG*: aminoglycoside. Gene names are in bold.

Homologues of aminoglycoside phosphorylation-encoding genes were also detected using a PCR-based approach, with both *aph* (2″)-Ic and *aph* (2″)-Id like genes being detected. These genes shared homology with genes from *Enterococcus* species, including *E. faecium* and *E. casseliflavus.* Aminoglycoside resistant *E. faecium* have received significant attention due to their role in nosocomial infections \[[@B58],[@B59]\]. Notably, the role of mobile genetic elements in the maintenance and dissemination of multi-drug resistance in *Enterococcus faecalis* and *E. faecium* has previously been highlighted \[[@B30],[@B60],[@B61]\]. While it is not certain that the genes identified in this study are also associated with mobile elements, the possibility that resistance genes could be transferred to commensals is a concern. Homologues of aminoglycoside adenylation genes, *ant* (2″)-Ia, were also successfully detected. These resembled genes from *Pasteurella*, *Acinetobacter* and *E. coli* (Table [3](#T3){ref-type="table"}), and the findings are thus consistent with previous research showing that these genes are most frequently detected in Gram negative bacteria \[[@B62]\]. Overall, the results demonstrate that the gut microbiota is a source of diverse aminoglycoside and β-lactam resistance genes, despite having had no recent antibiotic exposure. If these genes are expressed there is the potential that if antibiotic exposure occurred, bacteria containing these resistance genes would become the dominant component of the gut microbiota, as has been shown in previous studies \[[@B5],[@B63]\].

Conclusions
===========

This study has highlighted the merits of applying a PCR-based approach to detect antibiotic resistance genes within the human gut microbiome. The results clearly demonstrate that the human gut microbiota is a considerable reservoir for resistance genes. Further studies are required to determine the exact sources of these genes and to determine if they have the potential to become mobile. Additionally, we have highlighted the successful application of a PCR-based screen of a complex environment without prior isolation of resistant isolates. The possibility exists to couple this approach with lower throughput next generation sequencing strategies, such as that provided by the Ion PGM 314 chip, in instances where great diversity is likely. Our approach could also be used in conjunction with functional screening of metagenomic libraries to enable the detection of genes present in a complex environment at a low threshold and that may have avoided capture in the metagenomic library, as shown in a recent study \[[@B64]\]. Such a PCR-based approach is not being proposed as a substitute for ultra-deep high-throughput shotgun sequencing of metagenomic DNA, rather it is a lower cost, more targeted, alternative which facilitates the detection and *in silico* analysis of specific gene sets of interest. Finally, while this study demonstrates that the gut microbiota is a source of diverse resistance genes, further studies are required to investigate the exact sources of these genes, their expression and whether they have the potential to become mobile. As the scientific community continues to gain knowledge with respect to the genetic mechanisms involved in providing resistance to various antibiotics, the design of additional sets of degenerate primers will be possible and will provide further opportunities for the use of PCR to rapidly and efficiently detect antibiotic resistance genes in complex microbial environments, including the human gut microbiota.
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